Aptinyx Inc. (APTX) News
Filter APTX News Items
APTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest APTX News From Around the Web
Below are the latest news stories about APTINYX INC that investors may wish to consider to help them evaluate APTX as an investment opportunity.
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for NeuroscienceEVANSTON, Ill., November 10, 2022--Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations at the 52nd Annual Meeting of the Society for Neuroscience being held November 12-16, 2022 in San Diego, CA. The presentations include preclinical data supporting the development of NYX-783, an NMDA receptor positive allosteric modulator in post-traumatic |
BMO Capital Remains a Buy on Aptinyx (APTX)In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on Aptinyx (APTX - Research Report), with a price target of $2.00. The company's shares opened today at $0.31.Nachman covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Horizon Therapeutics, and AbbVie. According to TipRanks, Nachman has an average return of -9.1% and a 40.76% success rate on recommended stocks. Currently, the analyst consensus on Aptinyx is a Moderate Buy with an average price target of $1.67.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $3.76 and a one-year low of $0.20. |
Aptinyx Reports Third Quarter 2022 Financial Results and Recent HighlightsEVANSTON, Ill., November 08, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators. |
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH GrantEVANSTON, Ill., November 03, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the finalization of a $5.6 million grant under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, supporting the development of NYX-783 for the treatment of opioid use disorder (OUD). NYX-783 is an NMDA receptor positive allosteric modulator also in P |
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022EVANSTON, Ill., October 18, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights. |
10 Best Stocks to Buy Now According to Jeffrey Diehl’s Adams Street PartnersIn this article, we will be taking a look at some of the top stocks in the portfolio of Jeffrey Diehl. To skip our analysis of Jeffrey Diehl’s profile, investment strategy, and 13F holdings, you can go directly to see the 5 Best Stocks to Buy Now According to Jeffrey Diehl’s Adams Street Partners. Jeffrey […] |
Analysts’ Top Healthcare Picks: Pfizer (PFE), EDAP TMS (EDAP)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pfizer (PFE – Research Report), EDAP TMS (EDAP – Research Report) and Aptinyx (APTX – Research Report) with bullish sentiments. Pfizer (PFE) In a report released today, Colin Bristow from UBS maintained a Buy rating on Pfizer, with a price target of $59.00. The company's shares closed last Thursday at $47.90. According to TipRanks.com, Bristow 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.8% and a 32.3% success rate. |
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy BodiesEVANSTON, Ill., August 25, 2022--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment of 99 patients in the company’s ongoing Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies. Patients recently enrolled in the study are completing the 12-week treatment period and 30-day safety |
Bullish Aptinyx Inc. (NASDAQ:APTX) investors are yet to receive a pay off on their US$567k betInsiders who acquired US$567k worth of Aptinyx Inc.'s ( NASDAQ:APTX ) stock at an average price of US$2.34 in the past... |
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet GoalAptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline |